The estimated Net Worth of Gerrit Dispersyn is at least $849 Mille dollars as of 16 August 2021. Dr Dispersyn owns over 6,000 units of Phio Pharmaceuticals stock worth over $265,834 and over the last 8 years he sold PHIO stock worth over $0. In addition, he makes $583,142 as Pres e CEO & Director at Phio Pharmaceuticals.
Sign up
Dr D PHIO stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Phio Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of PHIO stock worth $9,780 on 16 August 2021.
The largest trade he's ever made was buying 6,000 units of Phio Pharmaceuticals stock on 16 August 2021 worth over $9,780. On average, Dr trades about 1,140 units every 108 days since 2017. As of 16 August 2021 he still owns at least 95,281 units of Phio Pharmaceuticals stock.
You can see the complete history of Dr Dispersyn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. biography
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. is the Pres, CEO & Director at Phio Pharmaceuticals.
What is the salary of Dr D?
As the Pres e CEO & Director of Phio Pharmaceuticals, the total compensation of Dr D at Phio Pharmaceuticals is $583,142. There are 1 executives at Phio Pharmaceuticals getting paid more, with Geert Cauwenbergh having the highest compensation of $625,901.
How old is Dr D?
Dr D is 46, he's been the Pres e CEO & Director of Phio Pharmaceuticals since . There are 4 older and 2 younger executives at Phio Pharmaceuticals. The oldest executive at Phio Pharmaceuticals Corp. is H. Paul Dorman, 79, who is the Independent Director.
What's Dr D's mailing address?
Gerrit's mailing address filed with the SEC is C/O PHIO PHARMACEUTICALS CORP., 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA, 01752.
Insiders trading at Phio Pharmaceuticals
Over the last 6 years, insiders at Phio Pharmaceuticals have traded over $0 worth of Phio Pharmaceuticals stock and bought 37,351 units worth $53,368 . The most active insiders traders include Geert Cauwenbergh, Keith L Brownlie e Patricia A Bradford. On average, Phio Pharmaceuticals executives and independent directors trade stock every 82 days with the average trade being worth of $6,130. The most recent stock trade was executed by Robert J Bitterman on 7 June 2024, trading 1,000 units of PHIO stock currently worth $740.
What does Phio Pharmaceuticals do?
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
What does Phio Pharmaceuticals's logo look like?
Complete history of Dr Dispersyn stock trades at Phio Pharmaceuticals
Phio Pharmaceuticals executives and stock owners
Phio Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Geert Cauwenbergh,
Director -
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D.,
Pres, CEO & Director -
Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc,
Pres, CEO & Director -
Tamara McGrillen,
IR Contact Officer -
Curtis Lockshin,
Independent Director -
Jonathan Freeman,
Independent Director -
H. Paul Dorman,
Independent Director -
John Barrett,
Chief Development Officer -
Gerrit Dispersyn,
President, Chief Executive Officer, Chief Operating Officer -
Robert Bitterman,
Independence Chairman of the Board -
Caitlin Kontulis,
VP of Fin. & Admin. and Sec. -
Patricia A Bradford,
Director -
Robert L Ferrara,
Director -
Keith L Brownlie,
Director -
Caitlin Kontulis,
Secretary & VP Finance & Admin -
Robert M. Infarinato,
VP, Chief Financial Officer